Mononucleosis News and Research

RSS

Study finds Epstein-Barr virus T-cells prevalent in early multiple sclerosis

A study led by UTHealth Houston reveals that T-cells specific for Epstein-Barr virus-infected cells are highly present in the cerebrospinal fluid of people with early-stage multiple sclerosis, suggesting a link between EBV and the disease.

8 Jan 2024

Research shows how the immune system keeps Herpes simplex virus at bay

Herpes simplex virus (HSV) is extremely common, affecting nearly two-thirds of the world's population, according to the World Health Organization.

14 Dec 2023

Researchers announce a new genetic classification system for gastric cancer

Professor Sang Cheul Oh of the Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Professor Sang‑Hee Kang of the Department of Surgery, Korea University's Guro Hospital, and Professor Sun Young Yim of the Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine announced a new genetic classification system for gastric cancer by a multicenter study with the University of Texas MD Anderson Cancer Center.

6 Nov 2023

Unveiling the role of EBV in the onset and progression of multiple sclerosis

Recent evidence strongly implicates infection by the Epstein-Barr virus (EBV) as the trigger for development of multiple sclerosis (MS). An international research team is now gathering to unveil the role of EBV in the onset and progression of the MS disease.

20 Sep 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

Unraveling the Epstein-Barr virus enigma: The puzzling role in multiple sclerosis development

Epstein-Barr virus (EBV) has a significant role in the development of multiple sclerosis (MS), with evidence linking EBV infection to increased MS risk and immune dysregulation. Understanding the mechanisms underlying this connection is crucial for advancing MS therapies and prevention strategies.

24 May 2023

Researchers show how the EBV virus exploits genomic weaknesses to cause cancer

The Epstein-Barr virus (EBV) is easily spread through bodily fluids, primarily saliva, such as kissing, shared drinks or using the same eating utensils.

13 Apr 2023

Study suggests psychosocial factors, not acute infections, contribute to long-COVID in young adults

Researchers investigated the prevalence of post-coronavirus disease 2019 condition in adolescents and young adults

4 Apr 2023

MedUni Vienna researchers identify specific immune response to Epstein-Barr virus

Medical science has not yet been able to explain why the Epstein-Barr virus triggers infectious mononucleosis (IM) in some people with initial infections and not in others.

19 Jan 2023

SARS-CoV-2 infection triggers reactivation of latent viruses in people with chronic fatigue syndrome

COVID-19 reactivated viruses that had become latent in cells following previous infections, particularly in people with chronic fatigue syndrome, also known as ME/CFS.

16 Nov 2022

Study shows the potential of experimental monoclonal antibodies to treat Epstein-Barr virus infection

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting.

27 Oct 2022

Why fatigue from long COVID goes beyond simply feeling tired

In a recent study posted to the medRxiv* preprint server, researchers in the Netherlands examined the role of inflammatory genes, cytotoxic T-lymphocytes (CD8+ T cells), and pro-inflammatory cytokines in long-lasting severe fatigue experienced by a large number of coronavirus disease 2019 (COVID-19) patients.

21 Sep 2022

The evolution of humoral immune responses over the course of Epstein-Barr virus infection

Researchers explored probable humoral immune mechanisms related to EBV curtailment, besides neutralization, by a systematic emphasis on antibody fragment crystallizable-functional activities over the course of EBV infections.

9 Sep 2022

NIH launches clinical study to evaluate an investigational preventative vaccine for Epstein-Barr virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV).

6 May 2022

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

Multiple sclerosis may be caused by infection with the Epstein-Barr virus

Multiple sclerosis (MS), a progressive disease that affects 2.8 million people worldwide and for which there is no definitive cure, is likely caused by infection with the Epstein-Barr virus (EBV), according to a study led by Harvard T.H. Chan School of Public Health researchers.

13 Jan 2022

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

Red blood cell distribution width as a biomarker for COVID-19

A review highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on COVID-19 and hepatitis.

22 Nov 2021

Study findings could lead to novel ways to overcome tumor resistance to immunotherapies

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Sep 2021

Cellular program could turn T cells into effective cancer killers

9 Sep 2021